drugset / Trial / NCT01793818

Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein

NCT01793818 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

Tat Oyi vaccination on seropositive patients could help their immune system to recognize and neutralize Tat. The neutralization of extra cellular Tat should help the cellular immune response to eliminate HIV-1 infected cells.

Timeline

Start
2013-02
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tat Oyi Vaccine 11 ug Other
Comparator Tat Oyi Vaccine 33 ug Other
Comparator Tat Oyi Vaccine 99 ug Other

Indications